Jasper Therapeutics Inc (JSPR)

Bought 20k so far ave .90,bids in for more if it dips

https://investorshub.advfn.com/stock-market/NASDAQ/jasper-therapeutics-JSPR/trades

Jasper Therapeutics shares rise 5% on clinical updates despite Q4 lossMarch 31, 2026 10:32 AM
IH Market News
Jasper Therapeutics Inc. (NASDAQ:JSPR) reported a fourth-quarter loss of $0.32 per share for the period ending December 31, 2025. The company currently generates no revenue, as it remains focused on clinical development of its lead drug candidate, briquilimab.Despite the loss, the biotechnology company’s shares climbed 5.44% in pre-market trading following the announcement, as investors reacted positively to recent clinical progress rather than the quarterly financial results.In January, Jasper said that 67% of additional patients enrolled in Cohort 9.1 of the BEACON study achieved a complete response at 12 weeks, with a mean UAS7 score reduction of 31 points.The company also reported that 75% of chronic spontaneous urticaria patients participating in the open-label extension study achieved either a complete response or well-controlled disease at 12 weeks.“Briquilimab has demonstrated the potential for a compelling and differentiated profile in both CSU and CIndU, along with proof of concept in asthma,” said Jeet Mahal, President and Chief Executive Officer of Jasper.“We are very pleased with the chronic urticaria data we reported in January from the BEACON study as well the open-label extension study, which reaffirmed the potential of briquilimab to drive rapid and durable disease control in patients,” he added.The company plans to begin enrolling patients in the Phase 2b portion of its Phase 2b/3 clinical study in chronic spontaneous urticaria during the second half of 2026, subject to available funding.Research and development expenses totaled $11.4 million in the fourth quarter, while general and administrative costs reached $4.5 million.For the full year 2025, Jasper reported a net loss of $75.8 million, or $3.95 per share. The company ended the year with $28.7 million in cash and cash equivalents, down from $71.6 million a year earlier.Jasper Therapeutics stock price

Original: Jasper Therapeutics shares rise 5% on clinical updates despite Q4 loss

Macd Crossed to bullish on 5 day chart,watching closely as death hr is ending at 11:30

JSPR..........................................................https://stockcharts.com/sc3/ui/?s=JAPR&p=W&b=5&g=0&id=p86431144783

Institutional Ownership 72.51%

Total Shares Outstanding (millions) 28
Total Value of Holdings (millions) $35

Active Positions | Holders | Shares
Increased Positions | 31 | 9,960,459
Decreased Positions | 39 | 2,336,667
Held Positions | 12 | 7,994,814
Total Institutional Shares | 82 | 20,291,940

https://www.nasdaq.com/market-activity/stocks/jspr/institutional-holdings

================

Jasper Therapeutics Analyst Ratings and Price Targets | NASDAQ:JSPR | Benzinga
Jasper Therapeutics Inc has a consensus price target of $25.7 based on the ratings of 18 analysts. The high is $86 issued by Stifel on June 27, 2024. The low is $4 issued by RBC Capital on November 11, 2025. The 3 most-recent analyst ratings were released by RBC Capital, Evercore ISI Group, and JMP Securities on November 11, 2025, September 22, 2025, and September 22, 2025, respectively. With an average price target of $8 between RBC Capital, Evercore ISI Group, and JMP Securities, there's an implied 296.04% upside for Jasper Therapeutics Inc from these most-recent analyst ratings.

https://www.benzinga.com/quote/JSPR/analyst-ratings

(Price targets are not always met)

$JSPR

1.93 Casper and Jasper

$2.10 Jasper the friendly ghost has risen 

GRABAR LAW OFFICE INVESTIGATES CLAIMS ON BEHALF OF SHAREHOLDERS OF JASPER THERAPEUTICS, INC. (NASDAQ: JSPR)
Grabar Law Office is investigating claims on behalf of shareholders of Jasper Therapeutics, Inc. (NASDAQ: JSPR). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
If you purchased Jasper Therapeutics, Inc. (NASDAQ: JSPR), shares prior to November 30, 2023, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Alternatively, Jasper shares between November 30, 2023 and July 3, 2025, you can participate in the class action Please visit https://grabarlaw.com/the-latest/jasper-shareholder-investigation/, contact Joshua Grabar at jgrabar @FH-6085.
JSPR

JSPR getting murderized this morning. $2.30 on bad drug lot news, results were positive but the drug lot problem killed it.

JSPR reports 5/19 according to Seeking Alpha

Looks like things may be perking up around here!!! Let's get dem super 7's tomorrow and then some!!!

Are we expecting another rebound boom this time around?

Rebound play

In some $5.60s what's the story here on beat down from $20

Entered today. 6.95 average. Bids sitting 6.90

Entered today. 6.95 average. Bids sitting 6.90

JSPR under $20

Rinse repeat back to $19 get out and play to $17

$15.87 + 5% low floater 10m .Most missed the early run to $19 rinse repeat

08:22 AM EDT, 10/14/2024 (MT Newswires) -- Jasper Therapeutics (JSPR) said Monday that preliminary data from its phase 1b/2a study of briquilimab showed that 93% of the adult participants with cold urticaria or symptomatic dermographism in both dose groups showed a clinical response to the treatment within six weeks.

In the 120mg dose cohort, 83% of participants experienced a complete response, the company said, adding briquilimab was well tolerated with no serious adverse events.

Jasper said that it secured regulatory clearance to enroll a 180mg dose cohort for the study and expects to report full trial data in the first half of 2025.

Shares of Jasper were up more than 15% in recent Monday premarket activity.

JSPR in an uptrend

Lets go. On out way to 30

JSPR 10Q due March 7

Nice thanks moving to $SUNW 52WL !

Looking good 90s is next thin !

90s very soon !

Nice squeeze at this level will be nice !
Waiting

https://ir.jaspertherapeutics.com/news-releases/news-release-details/jasper-therapeutics-announces-ind-clearance-phase-1b2a-study

https://x.com/wkrbnews/status/1709554398584578412?s=46&t=SOfgYFcNY1OxgkraPxHd4g

Pressure building up, let’s POP !

Let’s see some 90s and close the week strong !

Looking good !

Nice close !

80s close will be great !

Bid and volume creeping up, we need to hit 80s and I think the rest will be history, sure we will find out .

Nice healthy trading, next leg up should be coming soon, IMO .

Should see some 80s tomorrow, IMO .

Waiting !
$JSPR

Very thin all the way to 80s !

Needs volume !

Interesting PPS !

jspr vs ther

Strong buy ther
Reddit stock news

https://www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html

Yes it can today is day one hold tight $$$$&

This Can Fly High!

55 Minutes To Go!

SQUEEZE EM to $3 let’s gooooo$$$

JSPR: Kick-ASS!!!!

Hmmmm 1.80

Looking good I’m in $$$$ let’s goooo

$JSPR: Just spiked there to $2.10


Boooooooommmmmmmmmmmmmmmmmm


GO $JSPR